Journal of Critical Care
Volume 27, Issue 3 , Pages 322.e7-322.e14 , June 2012

The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: An important determinant of outcome

  • John G. Muscedere, MD

      Affiliations

    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7
    • Corresponding Author InformationCorresponding author. Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7.
    • ,
  • Andrew F. Shorr, MD

      Affiliations

    • Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC
    • ,
  • Xuran Jiang, MSc

      Affiliations

    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7
    • ,
  • Andrew Day, MSc

      Affiliations

    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7
    • ,
  • Daren K. Heyland, MSc, MD

      Affiliations

    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7
    • ,
  • for the Canadian Critical Care Trials Group

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Competing interests: Drs J. Muscedere and D. Heyland have received unrestricted research grants for studies in VAP unrelated to the present manuscript from Astra-Zeneca and Bayer Pharmaceuticals.

☆☆ Authors' contributions: JGM conceived of the study, participated in its design, and drafted the manuscript. DKH was the principal investigator of the Canadian VAP Study. XJ and AD acted as the study statisticians and conducted the data analysis. All authors provided input and suggestions on successive editions of the manuscript. All authors read and approved the final manuscript.

PII: S0883-9441(11)00436-9

doi: 10.1016/j.jcrc.2011.09.004

Journal of Critical Care
Volume 27, Issue 3 , Pages 322.e7-322.e14 , June 2012

Article Tools

* Image Usage & Resolution